BLTE — BELITE BIO INC
Public company
Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About BELITE BIO INC (BLTE)
BELITE BIO INC (BLTE) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Stanley Druckenmiller (Duquesne Family Office), valued at $17M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Tracked investors reporting BLTE
- Stanley DruckenmillerMar 31, 2026Duquesne Family OfficeShares106.1KValue$16.9M% Portfolio0.50%
- Ken GriffinDec 31, 2025Citadel AdvisorsShares5.1KValue$808% Portfolio0.00%
Recent activity
- $16.9MMay 15, 2026
- New$808Feb 17, 2026
- New$801.2KNov 14, 2025
Frequently asked questions
- How many institutional investors hold BLTE?
- 2 tracked institutional investors disclosed a position in BLTE (BELITE BIO INC) in their most recent 13F filing.
- Who is the largest institutional holder of BLTE?
- Stanley Druckenmiller, Duquesne Family Office, holds the largest disclosed position in BLTE, valued at $17M.
- Did institutional ownership of BLTE increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 fully exited BLTE.
- Where does this BLTE ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.